capAI PLC - Commercial and Strategy Update, Fundraising
THIS ANNOUNCEMENT ("ANNOUNCEMENT") AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF THE DOMESTIC LAW OF THE

capAI plc
(the "Company" and, together with its subsidiaries, the "Group" or "capAI")
Commercial and Strategy Update, Conditional Placing and Subscription
capAI plc (LSE: CPAI, OTCQB: CPIQF) is pleased to provide a strategic update on the continued development of its portfolio across preventative health, media platforms and the development and commercialisation of associated content, supported by AI-enabled commercial execution tools, and to announce a conditional fundraise of
Highlights:
· capMedical, Inc. ("capMedical", the Group's preventative health subsidiary) longevity programmes under development, offering tiered preventative health solutions ranging from
· capMedia, Inc. ("capMedia", the Group's content and publishing subsidiary) expanding publishing pipeline with both non-fiction and fiction titles, leveraging Author42 platform with initial revenues being generated
· AI Growth Hacking Tool concept in development to accelerate customer acquisition and commercial execution across both verticals, with potential to be a standalone product in due course
· Conditional fundraise of
· Proceeds to support platform development, early-stage commercialisation, and partnership structuring across capMedical and capMedia
· Group continues to operate capital-light model with no obligation to complete platform acquisitions, maintaining strategic flexibility
The Company's strategy remains to build and selectively scale a diversified portfolio of AI-enabled platforms across multiple verticals, while retaining flexibility to allocate capital and management resource dynamically as opportunities evolve.
capAI will continue to assess opportunities across its verticals, prioritising those that offer scalable economics, strong margin potential and alignment with the Company's long-term objective of building sustainable shareholder value.
capMedical: Longevity Programmes (subject to licensing discussions)
Since the incorporation of capMedical in
capAI is currently evaluating the launch of longevity and preventative health programmes through its capMedical vertical. This represents the Company's initial area of focus within capMedical and is intended to combine diagnostics, expert interpretation and structured health optimisation pathways across a range of price points.
Offerings under these new programmes will range between approximately
capAI expects the initial rollout of capMedical longevity services to be based in
Programme tiers are expected to include:
· Entry-level diagnostic packages (c.
· Mid-tier programmes (up to c.
· Premium programmes (up to c.
The progression of these longevity programmes remains subject to the successful conclusion of ongoing licensing discussions, including with R42 Group, LLC, and there can be no certainty at this stage that these discussions will result in a binding agreement.
capAI expects that, if successfully licensed and implemented, a tiered approach to longevity and preventative health could address demand across both mainstream preventative healthcare markets and premium health optimisation segments, while remaining consistent with the Company's capital-efficient strategy.
capMedia: Expanded Publishing Pipeline and Multi-Format IP Commercialisation
capAI is also pleased to announce that capMedia is leveraging its Author42 platform to develop and deliver both non-fiction and - as of
Current planned titles in development include:
· AI and Finance;
· A Crash Course in AI;
· Aging Science; and
· New Fiction Titles (in development).
The Group notes that the soft commercial launch of Author42, as announced in
In parallel, capMedia continues to advance its longer-term IP commercialisation strategy through its Creator42 and Game42 platforms, pursuing additional downstream value through:
· Book-to-Movie / Book-to-TV development opportunities, including screenplay adaptation, licensing, and strategic production partnerships; and
· Book-to-Game concepts, including interactive entertainment and narrative-driven game formats.
Further to recent updates, the Company expects that a completion notice in respect of Game42 is anticipated during Q1 2026, subject to the satisfaction of relevant conditions.
AI Growth Hacking Tool Concept: Accelerating Commercial Execution
capAI is also developing an AI Growth Hacking Tool concept intended to support customer acquisition, engagement optimisation, and conversion performance across both capMedical and capMedia initiatives.
The Group believes that as the cost of customer acquisition rises globally, the ability to deploy AI-driven optimisation across marketing funnels, content strategy, and performance analytics can become a meaningful competitive advantage.
capAI's AI Growth Hacking Tool concept is designed to provide capabilities such as:
· AI-assisted campaign generation and rapid iteration;
· Data-driven optimisation of customer journeys and conversion flows;
· Automated content scheduling, distribution, and performance learning loops; and
· Structured experimentation frameworks to support scalable growth.
The Group believes this platform has the potential to enhance operational efficiency, shorten time-to-revenue, and generate valuable proprietary data insights. CapAI may also explore the opportunity to commercialise this tool as a standalone AI product offering in due course.
Cost Base and Strategic Outlook
capAI continues to operate with a very modest cost base, reflecting its early stage, focus on capital discipline and management alignment. The Company notes that its Executive Chairman,
The Board believes that capAI's diversified platform strategy - spanning preventative health and longevity, publishing and downstream content opportunities, and AI-enabled commercial execution - provides multiple potential routes to revenue, thus managing risk, while maintaining capital discipline and strategic flexibility.
capAI will continue to assess opportunities across its verticals, prioritising those that offer scalable economics, strong margin potential and alignment with the Company's long-term objective of building sustainable shareholder value.
Conditional Placing and Subscription to Support Platform Development
The Company is further pleased to announce that it has conditionally raised gross proceeds of
Details of the Fundraise
The Company has conditionally raised:
·
·
The Fundraise has not been underwritten. Application has been made for the Fundraise Shares to be admitted to trading on the main market for listed securities of London Stock Exchange plc ("Admission"). It is expected that Admission will become effective and that dealings in the Fundraise Shares will commence, at
Director Participation
The Directors of the Company have participated in the Fundraise as follows:
· Professor
·
This participation demonstrates the Board's continued alignment with shareholder interests and confidence in the Group's strategy and execution capability.
AlbR Capital acted as the Company's broker in connection with the Placing.
In connection with the Fundraise, the Company will issue Ordinary Shares with an aggregate value of
Total Voting Rights
Following Admission, the Company's issued share capital will comprise 421,143,063 Ordinary Shares. The Company does not hold any shares in treasury. Therefore, the total number of voting rights in the Company following Admission will be 421,143,063.
In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, this figure of 421,143,063 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Further updates will be provided as appropriate, in line with the Company's disclosure obligations.
Commenting, Professor
"We continue to execute on our strategy of building a diversified portfolio of AI-enabled platforms across healthcare and media, supported by content-led commercial opportunities and delivered through a disciplined, capital-light operating model.
Our initial focus within capMedical reflects demand for preventative and longevity-oriented healthcare solutions, while our progress across capMedia highlights how shared platforms and scalable intellectual property can support multiple, complementary routes to value over time.
I am particularly enthused by our inaugural concept within capMedical. While there is a broad range of products already available in the market, we believe our potential competitive edge lies in offering a more comprehensive and consolidated approach to ageing, spanning brain, metabolic, cardiovascular, skin and facial, and immune system health, relative to solutions that are either more fragmented or consolidated but less comprehensive in scope."
For the purposes of
Enquiries
Company:
capAI plc hello@capaiplc.com
Broker:
AlbR Capital Limited Tel: +44 (0) 207 469 0930
Director's Dealing Notification
The information set out below is provided in accordance with the requirements of Article 19(3) of
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
|
||||
|
2 |
Reason for Notification |
|||||
|
a) |
Position/status |
Executive Director, PDMR |
||||
|
b) |
Initial notification/amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
capAI plc |
||||
|
b) |
LEI |
213800IVPZ932NP24O44 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of |
||||
|
|
Identification code |
|
||||
|
b) |
Nature of the transaction |
Subscription of Ordinary Shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information |
|
||||
|
|
- Aggregated volume |
n/a |
||||
|
|
- Price |
|
||||
|
e) |
Date of the transaction |
|
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Professor |
||||
|
2 |
Reason for Notification |
|||||
|
a) |
Position/status |
Executive Director, PDMR |
||||
|
b) |
Initial notification/amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
capAI plc |
||||
|
b) |
LEI |
213800IVPZ932NP24O44 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of |
||||
|
|
Identification code |
|
||||
|
b) |
Nature of the transaction |
Subscription of Ordinary Shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information |
|
||||
|
|
- Aggregated volume |
n/a |
||||
|
|
- Price |
|
||||
|
e) |
Date of the transaction |
|
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
Important Legal Information
The contents of this Announcement have been prepared by, and are the sole responsibility of, the Company.
This Announcement does not constitute, contain or form part of any offer of transferable securities to the public within the meaning attributed to that phrase by section 102B of Financial Services and Markets Act 2000 (as amended) ("FSMA").
The Fundraise Shares have not been and will not be registered under the
This Announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this Announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this Announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this Announcement applies only as of the date of this Announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this Announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this Announcement is based, unless required to do so by applicable law.
No prospectus, offering memorandum, offering document or admission document has been or will be made available in any jurisdiction in connection with the matters contained or referred to in this Announcement and no such document is required (in accordance with Regulation (EU) No 2017/1129 or the Public Offers and Admissions to Trading Regulations 2024) to be published.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE